<?xml version='1.0' encoding='utf-8'?>
<document id="23118326"><sentence text="Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib."><entity charOffset="68-79" id="DDI-PubMed.23118326.s1.e0" text="carfilzomib" /></sentence><sentence text="Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM)"><entity charOffset="0-11" id="DDI-PubMed.23118326.s2.e0" text="Carfilzomib" /></sentence><sentence text=" Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib"><entity charOffset="110-121" id="DDI-PubMed.23118326.s3.e0" text="carfilzomib" /></sentence><sentence text=" The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM"><entity charOffset="11-22" id="DDI-PubMed.23118326.s4.e0" text="carfilzomib" /></sentence><sentence text=" Metabolites of carfilzomib were characterized in patient plasma and urine samples"><entity charOffset="16-27" id="DDI-PubMed.23118326.s5.e0" text="carfilzomib" /></sentence><sentence text=" In vitro drug metabolism and DDI studies were conducted in human liver microsomes and hepatocytes" /><sentence text=" A clinical DDI study was conducted in patients with solid tumors to evaluate the effect of carfilzomib on CYP3A activity"><entity charOffset="92-103" id="DDI-PubMed.23118326.s7.e0" text="carfilzomib" /></sentence><sentence text=" Plasma concentrations of carfilzomib declined rapidly and in a biphasic manner after intravenous administration"><entity charOffset="26-37" id="DDI-PubMed.23118326.s8.e0" text="carfilzomib" /></sentence><sentence text=" The systemic half-life was short and the systemic clearance rate was higher than hepatic blood flow" /><sentence text=" Carfilzomib was cleared largely extrahepatically via peptidase cleavage and epoxide hydrolysis"><entity charOffset="1-12" id="DDI-PubMed.23118326.s10.e0" text="Carfilzomib" /><entity charOffset="77-84" id="DDI-PubMed.23118326.s10.e1" text="epoxide" /><pair ddi="false" e1="DDI-PubMed.23118326.s10.e0" e2="DDI-PubMed.23118326.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23118326.s10.e0" e2="DDI-PubMed.23118326.s10.e1" /></sentence><sentence text=" Cytochrome P450-mediated metabolism played a minor role, suggesting that coadministration of P450 inhibitors or inducers is unlikely to change its PK profile" /><sentence text=" Carfilzomib showed direct and time-dependent inhibition of CYP3A in human liver microsome preparations and exposure to carfilzomib resulted in reductions in CYP3A and 1A2 gene expression in cultured human hepatocytes"><entity charOffset="1-12" id="DDI-PubMed.23118326.s12.e0" text="Carfilzomib" /><entity charOffset="120-131" id="DDI-PubMed.23118326.s12.e1" text="carfilzomib" /><pair ddi="false" e1="DDI-PubMed.23118326.s12.e0" e2="DDI-PubMed.23118326.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23118326.s12.e0" e2="DDI-PubMed.23118326.s12.e1" /></sentence><sentence text=" However, administration of carfilzomib did not affect the PK of midazolam in patients with solid tumors, and there were no safety signals indicative of potential drug interactions"><entity charOffset="28-39" id="DDI-PubMed.23118326.s13.e0" text="carfilzomib" /><entity charOffset="65-74" id="DDI-PubMed.23118326.s13.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.23118326.s13.e0" e2="DDI-PubMed.23118326.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23118326.s13.e0" e2="DDI-PubMed.23118326.s13.e1" /></sentence><sentence text=" We conclude that the rapid systemic clearance and short half-life of carfilzomib limit clinically significant DDI"><entity charOffset="70-81" id="DDI-PubMed.23118326.s14.e0" text="carfilzomib" /></sentence><sentence text="" /></document>